Tumor Tissues and Non-tumor Tissues From PDAC Patients Were Used for Genomic and Transcriptome Sequencing Analysis and Proteomics and Phosphorylated Proteomics
Conditions
Brief summary
A large-scale, high-throughput, multi-dimensional comprehensive study of PDAC multiomics will be carried out. In this study, clinical specimens of resected PDAC collected by our research group from 2017 to 2019 will be selected as research objects.Tumor tissues and their adjacent non-tumor tissues from more than 200 PDAC patients are expected to be used for genome, transcriptome sequencing and mass spectrometry analysis of proteome and phosphorylated proteome.Combined with the data results of multiomics, bioinformatics analysis and network database information, we will clarify the relationship between multiomics of pancreatic cancer and established the new subtyping of pancreatic cancer proteome. A molecular landscape of the progression of pancreatic cancer at the genome-transcriptome-proteome level provides new therapeutic targets to improve the prognosis of this deadly disease.
Interventions
OTHERNo intervention
No intervention
Sponsors
Ruijin Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. The diagnosis of pancreatic cancer was confirmed by histological examination or fine needle aspiration cytology; 2. The tumor was graded according to THE WHO standard, and the tumor stage was graded according to the TNM stage;
Exclusion criteria
1. The inclusion criteria of the above groups were not met; 2. There are few tissue specimens, only enough for clinical diagnosis; 3. Patients are unwilling to conduct follow-up study; 4. For the new diagnosed patient, radiotherapy or chemotherapy have been given in the previous three months;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Integrative Proteomic Characterization of PDAC | Two yeaers | The genome-transcriptome proteome level provides a molecular landscape of the progression of pancreatic cancer, providing new therapeutic targets to improve the prognosis of PDAC |
Countries
China
Contacts
Primary ContactHao Chen, MD
Backup ContactLingxi Jiang, Ph.D
Outcome results
None listed